Shop Antibodies

Custom Antibody Production with Guaranteed Success

(2 customer reviews)

$1,750.00$14,500.00

The binding affinity and specificity are the key indicators of a successful antibody. The majority of existing antibodies were raised against either full-length protein antigens (>200 amino acids) or long-peptide (>20 amino acids) antigens. Full-length protein antigens often cause promiscuous bindings in antibody due to the large number of potential binding sites. Long peptides are very difficult to dissolve into water even in the presence of DMSO. They must be denatured prior to conjugation to carrier proteins, which is the major cause of non-specific or off-target binding.

BiCell Scientific® researchers have discovered that short-peptide antigens (13-19 amino acids) allow developing polyclonal and monoclonal antibodies with specific and bona fide binding to target proteins in their native conformation. Because the structural length of an antibody binding site spans 8 amino acids in a target protein, short-peptide antigens contain a limited number (often <10) of potential binding sites. This feature is particularly important for developing “precision” antibodies with improved binding specificity to suit high-resolution applications, such as immunohistochemistry studies that require undenatured proteins to be recognized in situ among millions of other proteins. Short antigen sequences also allow antibodies to be used in protein domain specific or amino acid site specific recognition.

Custom ordering polyclonal antibodies takes 7-12 weeks depending upon antigen sequence. Target proteins will be analyzed by advanced algorithms based upon DeepMind’s AlphaFold protein structures to facilitate the rational design of peptide antigens. Short peptide antigens (13-19 amino acid long) ensures high specificity of antibody binding and allows developing site-specific antibodies that can recognize point mutation, phosphorylation, acetylation, methylation and many other forms of modification in target proteins. Custom ordered antibodies will be manufactured, purified and validated against human or rodent tissues using ELISA and immunofluorescence labeling techniques. Successful binding signals are guaranteed. Projects that fail to produce meaningful binding signals will be fully refunded.

Custom ordering monoclonal antibodies takes 3-5 months depending upon antigen sequence. Target proteins will be analyzed by advanced algorithms to facilitate the rational design of peptide antigens. An antigen binding assay will be implemented to screen for the antibody secreting hybridoma cells. Both recombinant full-length protein antigen and short peptide antigen can be used to make monoclonal antibody. Short peptide antigens also allow making site-specific monoclonal antibodies. Custom ordered antibodies will be manufactured, purified and validated against human or rodent tissues using ELISA and immunofluorescence labeling techniques. One validated hybridoma cell line will be provided in addition to the purified antibody. Successful binding signals are guaranteed. Projects that fail to produce meaningful binding signals will be fully refunded.

Protein modifications that can be targeted for site specific polyclonal or monoclonal antibody production:
        – Acetylation;   Cleavage sites;   Drug binding Isoforms;   Glycosylation;   Ligand binding;   Myristolation;   
        – Phosphorylation;   Prenylation;   Splice variants;   Sumoylation;   Ubiquitination;   Mutations/Polymorphisms.

All animal work is performed at St Louis University Department of Comparative Medicine and approved by IACUC under animal use protocol number AUP #2943.

Item Cat No.: N/A

Custom antibody production service is offered with guaranteed binding signals to meet with customer’s needs and requirements.

Product price
Additional options total:
Order total:
Please enter a Target Protein Name.
Please enter a NCBI Accession Number.

Completed Custom Antibody Projects (For Academic Users)

 

Heinrich-Heine-Universität Düsseldorf, Germany

  • anti-Kif24 polyclonal antibody
  • anti-HDAC6 polyclonal antibody
  • anti-Ofd1 polyclonal antibody
  • anti-KIAA0408 polyclonal antibody

Harvard Medical School

  • anti-Mlck1 polyclonal antibody

University of Washington

  • anti-Armc9 polyclonal antibody
  • anti-Togaram1 polyclonal antibody
  • anti-KIAA0586 polyclonal antibody

University of Pittsburgh

  • anti-Cubilin polyclonal antibody

MD Anderson Cancer Center

  • anti-Ntrk2 polyclonal antibody

NCVC, Japan

  • anti-Tm9sf3 polyclonal antibody
  • anti-Slc12a8 (mouse) polyclonal antibody
  • anti-Slc12a8 (Zebrafish) polyclonal antibody
  • anti-Cadherin-6 (Zebrafish) polyclonal antibody

Uppsala University, Sweden

  • anti-PIK3CA point mutation specific polyclonal antibody

Harvard Medical School

  • anti-Mlck1 monoclonal antibody

Yale University

  • anti-Pcdhga9 monoclonal antibody

Heinrich-Heine-Universität Düsseldorf, Germany

  • anti-KIAA0408 isoform specific polyclonal antibody

Harvard Medical School

  • anti-Cldn2 monoclonal antibody

University of Virginia

  • anti-MKS3 (Xenopus) polyclonal antibody

Heinrich-Heine-Universität Düsseldorf, Germany

  • anti-KIAA0408 N-terminus monoclonal antibody

Yale University

  • anti-Pkd1 (human) monoclonal antibody
  • anti-Pkd2 (human) monoclonal antibody

University of Cambridge, England

  • anti-Llgl2 polyclonal antibody

Harvard Medical School

  • anti-Mlck1 polyclonal antibody (10mg scale)

University of Washington

  • anti-Togaram1 monoclonal antibody

University of Paris, France

  • anti-Nphp1 monoclonal antibody

University of Cambridge, England

  • anti-Epb41l5 polyclonal antibody

Institut Pasteur de Lille, France

  • anti-Sglt4 polyclonal antibody

Additional information

Purified Antibody Deliverable

1 mg of Polyclonal Antibody Production, 1 mg of Monoclonal Antibody Production and 1 Hybridoma Cell Line, 1 mg of Site-specific Polyclonal Antibody Production, 1 mg of Site-specific Monoclonal Antibody Production and 1 Hybridoma Cell Line, 10 mg of Polyclonal Antibody Production

Host Species

Rat, Mouse, Rabbit

2 reviews for Custom Antibody Production with Guaranteed Success

  1. BiCell Tech Team

    Claudin-2 has been a problem in terms of antibody detection for some time. We have tested most commercial monoclonal and polyclonal antibodies and had only occasionally found a polyclonal that works well across applications, including immunostaining of formalin-fixed paraffin-embedded tissues. Unfortunately, polyclonal antibodies purchased from can vendors very over time. We therefore tried to make our own monoclonal antibodies to claudin-2 and failed on 2 different attempts with an approach that had worked well for ZO-1 and occludin monoclonal antibodies. BiCell approached the problem differently in terms of antigen analysis, screening, and other unique aspects of their technique. As a result, we developed several outstanding monoclonal anti-claudin-2 antibodies. The one shown, clone E5, outperforms all previous antibodies, monoclonal and polyclonal, that we have used across all applications, including western blot, immunofluorescent staining of cultured cells, and immunofluorescent staining of tissues.
    BiCell Tech Team posting review on behalf of Dr. Jerrold Turner, Dr. Shabnam Abtahi, Harvard Medical School

  2. jhou23

    Paraffin embedding and subsequent antigen retrieval protocols probably have caused minute changes in target protein folding structure, which make target protein different from that in cryosections or in live cells. Monoclonal antibodies raised against short peptide epitope likely will offer a wide range of binding affinities to suit different protein folding patterns in FFPE, cryosection or live cells, because short peptides in solution assume a wide range of folding possibilities, some of which will resemble FFPE. Full-length protein antigens likely have rigid structures. Antibodies raised against full-length proteins may only recognize a few protein folding possibilities.

Add a review

"I am really impressed with your approach. We tried multiple times previously to create monoclonal and polyclonal antibodies to claudin-2 and MLCK1. We have had limited success generating polyclonals and no success generating monoclonals. You have generated outstanding monoclonals to both. I look forward to continuing to work with you."

Jerrold R. Turner, M.D., Ph.D.

Brigham and Women’s Hospital | Harvard Medical School

"The polyclonal antibody you generated for KIAA0408 is stunning! KIAA0408 is a novel cilium molecule that has never been studied. So, clearly there will be a lot of demand for it as we have discovered a very interesting finding and the story will be published in a high impact journal. I am strongly inclined to generate monoclonal antibody for this protein too and we should think about patenting it."

Univ.-Prof. Jay Gopalakrishnan PhD

Heinrich-Heine-Universität | Universitätsklinikum Düsseldorf

"Your ARL13B antibody works beautifully!!! We’re so happy to have a cilia-specific antibody made in rat! I can send you high resolution images to be posted on your website."

Julie Craft Van De Weghe, PhD

School of Medicine | University of Washington

"The assay is a homophilic interaction mediated cell adhesion on purified protein (in this case, immobilized purified Pcdhga9 to Pcdhga9 expressed on cell surface). Compared to control, cell adhesion is reduced in the presence of Pcdhga9 monoclonal antibody supernatants!"

Divyesh Joshi, PhD

School of Medicine | Yale University

Contact us for questions or custom requests!